CSL Ltd Annual Report 2019

35+ Countries of operations around theworld US$8.5 Billion in annual revenue US$3.3 Billion in R&D investments in the last 5 years advances product pipeline 25,000+ Employees around the world 1,700+ R&D employees 230+ Plasma collection centres across Europe and North America 3 CSL is a global biotechnology leader which develops and delivers innovative medicines that save lives, protect public health and help people with life-threatening medical conditions live full lives. In the past century, CSL has grown to become the world’s fifth largest biotechnology company with more than 25,000 employees bringing lifesaving medicines to people in nearly 70 countries. CSL at a glance Our businesses CSL Behring CSL Behring is a global leader in developing and delivering high quality medicines that treat people with rare and serious diseases. Our treatments offer promise for people who are living with conditions in the immunology and neurology; haematology and thrombosis; cardiovascular and metabolic; respiratory; and transplant therapeutic areas. CSL Behring drives more than 85% of overall company revenue with substantial markets in Asia Pacific, Europe and North America. Seqirus Seqirus was established on 31 July 2015, following CSL’s acquisition of the Novartis influenza vaccines business, and subsequent integration with bioCSL. As one of the largest influenza vaccine providers in the world, Seqirus is a major contributor to the prevention of influenza globally and a transcontinental partner in pandemic preparedness. Seqirus operates state-of-the-art production facilities in the United States (US), the United Kingdom (UK) and Australia and utilises both egg-based and cell-based manufacturing technologies as well as a proprietary adjuvant. It has leading research and development (R&D) capabilities, a broad and differentiated product portfolio and commercial operations in more than 20 countries. CSL Limited Annual Report 2019 6 Our Company